The purpose of this study is to evaluate the concentrations of IL-1β, IL-1RA, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p70, IL-13, IL-15, IL-17A, TNF-α, VEGF, PDGF-bb, GM-CSF, G-CSF, and FGF-basic in the CSF of patients with newly diagnosed relapsing-remitting multiple sclerosis (RRMS) and a group of healthy control subjects without demyelinating brain lesions. This evidence concerns the gene CSF2 and relapsing-remitting multiple sclerosis.